Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide
 on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis
 (RRMS) from French Observatory of Multiple Sclerosis (French MS cohort )
Inclusion Criteria:

 -  RRMS Patients with an EDSS score ranging between 0 and 5.5, who initiated either DMF
 or Teriflunomide before 1/01/2016 and with an available MRI scan and EDSS assessment
 respectively within 12 and 6 months before treatment initiation Patients who had
 consent to OFSEP registry Naive patient or treated with prior first line treatment :
 interferon, glatiramer acetate

 Exclusion Criteria:

 -  Patient with progressive multiple sclerosis

 -  Patients with prior second line Patient with no MRI or EDSS score within the year
 before DMF or Teriflunomide initiation.